The GMP Manufacturing Facility enables Cancer Institute (WIA) to translate laboratory discoveries into clinical-grade cellular therapies. Designed to meet national and international regulatory standards, the facility supports the production of CAR-T cells, dendritic cell vaccines, and other advanced therapy medicinal products. Rigorous quality control and environmental monitoring ensure product safety and consistency throughout the manufacturing process.
Cleanroom suites classified to ISO 7 and ISO 5 standards for aseptic processing
Closed-system cell expansion and activation using automated bioreactors
Lentiviral and retroviral vector production for gene-modified cell therapies
In-process and release testing including sterility, endotoxin, and potency assays
Cryopreservation and controlled-rate freezing of cellular products
Quality management system aligned with CDSCO and WHO GMP guidelines
Researchers interested in using this facility can request access by contacting the facility management team. Training sessions and orientation are available for new users.
Direct Enquiry: facilities@cancerinstitutewia.org
.png&w=96&q=75){kind=small}